March 3, 2025 - 13:32

In a significant move within the Indian financial landscape, Shapoorji Pallonji Group is actively seeking to engage in private credit deals. This initiative comes as the conglomerate aims to diversify its funding sources amid a competitive market environment. The group's decision reflects a growing trend among large corporations to tap into private credit as a means of financing their expansive projects.
The private credit market in India has been gaining traction, offering an alternative to traditional bank loans. This shift is particularly relevant as businesses look for more flexible and tailored financing solutions. Shapoorji Pallonji's exploration of this avenue is indicative of its strategic approach to capital management, especially in light of the ongoing economic fluctuations.
Industry analysts suggest that such moves could enhance the group's financial resilience and enable it to seize new opportunities in the real estate and infrastructure sectors. As the demand for private credit continues to rise, Shapoorji Pallonji's foray into this space may set a precedent for other companies in the region.
June 8, 2026 - 22:27
What history tells us about Marvell's upcoming S&P 500 inclusionMarvell Technology shares have been climbing sharply after the announcement that the company will join the S&P 500 index on June 22. Investors are betting that the move will bring fresh demand from...
June 8, 2026 - 04:51
Is PDD Holdings Inc. (PDD) A Good Stock To Buy Now?A recent discussion on a value investing forum laid out a bullish case for PDD Holdings Inc., the parent company of e-commerce platforms Temu and Pinduoduo. As of late May, shares were trading near...
June 7, 2026 - 03:13
Apple Stock: Buy, Sell, or Hold?Apple`s stock is trading close to an all-time high, and a series of potential catalysts could sustain the upward momentum. The company continues to benefit from strong demand for its latest iPhone...
June 6, 2026 - 22:38
Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are MissingEli Lilly is making a serious push into the vaccine business. The pharmaceutical giant announced a trio of acquisitions totaling $3.8 billion, aimed at building a new division focused on infectious...